FIELD: chemistry.
SUBSTANCE: invention refers to heterocyclic compounds of formula (I) or to therapeutically acceptable salt thereof, where X represents benzo [d] thiazolyl, optionally substituted with one or two R4; Y1 represents a pirrolil, pyrazolyl, triazolyl or pyridinyl; where Y1 is optionally substituted with one or two substitutes independently selected from a group consisting of R5, CO(O)R5, CO(O)H and CN; L1 selected from group comprising (CR6R7)q, (CR6R7)s-O-(CR6R7)r, (CR6R7)s-C(O)-(CR6R7)r, (CR6R7)s-S(O)2-(CR6R7)r and (CR6R7)s-NR6A-(CR6R7)r; and Y2 is selected from a group consisting of C3-4 alkyl with branched chain, C5-7 cycloalkyl, C6-7 cycloalkyl, phenyl, piperidinyl, morpholinyl and tetrahydropiranyl; where the phenyl is optionally condensed with benzene; where Y2 optionally substituted with one, two or three substitutes independently selected from a group consisting of R8, OR8, SO2R8, CO(O)R8, NHR8, N(R8)2, C(O)H, OH, CN, NO2, F, Cl, Br and I; or L1 represents a bond; and Y2 is selected from a group consisting of C5 cycloalkyl, phenyl, tetrahydropiranyl and piperidinyl; where C5 cycloalkyl and tetrahydropiranyl presented by Y2 are optionally condensed with benzene; Z1 is selected from group consisting of 
or 
; R1, R2 and R3 are absent; R4, in each case is independently selected from group consisting of OR12 and halogen; R5, in each case is independently selected from group consisting of C1-6 alkyl, C1-6 hydroxyalkyl, phenyl and cyclopropyl; R6A represents C1-6 alkyl; each R6 and7, in each case are independently selected from group consisting of hydrogen, R15 and CO(O)R15; R8, in each case is independently selected from group consisting of C1-6 alkyl, C2-6 alkynyl, phenyl, piperidinyl and morpholinyl; where R8
C1-6 alkyl and C2-6 alkynyl are optionally substituted with one, two or three substitutes independently selected from a group consisting of R16, OR16, SO2R16, C(O)R16, NHR16, N(R16)2, OH and F; where R8 phenyl is optionally substituted with one Cl; Rk, in each case represents C1-6 alkyl; R12 is C1-4 alkyl; R15, in each case is independently selected from a group consisting of C1-4 alkyl and phenyl; where R15 C1-4 alkyl is optionally substituted with one substitute selected from a group consisting of C1-4 alkoxy, morpholinyl and C6cycloalkyl; R16, in each case is independently selected from a group consisting of C1-4 alkyl, C1-4 hydroxyalkyl, phenyl, tetrahydropiranyl, morpholinyl, 1,4-dioxanyl, dioxydotiomorfolinyl and pyridinyl; q equals to 1, 2 or 3; s, r, m, n and p equals to 0; or where the compound is selected from a group specified in item 1. Invention also relates to pharmaceutical composition based on the above compounds and method of cancer treating.
EFFECT: technical result allows obtaining new heterocyclic compounds effective in cancer treating.
9 cl, 3 tbl, 188 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 8-CARBAMOYL-2-(2,3-DI-SUBSTITUTED PYRID-6-YL)-1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES AS APOPTOSIS-INDUCING AGENTS FOR CANCER TREATMENT | 2012 |
|
RU2625315C2 |
| HETEROCYCLIC COMPOUNDS AND METHODS OF APPLICATION | 2009 |
|
RU2525116C2 |
| ANTIBODIES TO B7-H3 AND CONJUGATES OF ANTIBODY AND DRUG | 2017 |
|
RU2764651C2 |
| COMPOUNDS AND METHODS FOR USING | 2009 |
|
RU2561109C2 |
| SUBSTITUTED CHROMANS | 2015 |
|
RU2718060C2 |
| PYRIDINES SUBSTITUTED WITH HETEROARYL AND APPLICATION METHODS | 2017 |
|
RU2756743C2 |
| PRIMARY CARBOXAMIDES AS BTK INHIBITORS | 2014 |
|
RU2708395C2 |
| NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES USEFUL AS PLASMA KALLIKREIN INHIBITOR | 2014 |
|
RU2712621C2 |
| DERIVATIVES OF BENZIMIDAZOL INHIBITING FACTOR Xa | 2004 |
|
RU2346944C2 |
| ENZYMES INHIBITION | 2013 |
|
RU2638537C2 |
